Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 2017 (2017), Article ID 1430350, 12 pages
https://doi.org/10.1155/2017/1430350
Review Article

Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives

1Department of Biochemistry and Molecular Biology, University of Texas Medical School at Houston, Houston, TX 77030, USA
2Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX 77030, USA
3Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital, Houston, TX 77030, USA

Correspondence should be addressed to Harry Karmouty-Quintana; ude.cmt.htu@ytuomrak.yrrah

Received 18 November 2016; Accepted 19 January 2017; Published 13 February 2017

Academic Editor: Elie El Agha

Copyright © 2017 Scott D. Collum et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. CDC, National Center for Health Statistics—Leading Causes of Death, September 2016, http://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm.
  2. The Lancet Respiratory Medicine, “Lung disease left out in the cold,” The Lancet Respiratory Medicine, vol. 4, no. 7, p. 527, 2016. View at Publisher · View at Google Scholar
  3. A. Chaouat, R. Naeije, and E. Weitzenblum, “Pulmonary hypertension in COPD,” European Respiratory Journal, vol. 32, no. 5, pp. 1371–1385, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. R. Klinger, “Group III pulmonary hypertension: pulmonary hypertension associated with lung disease: epidemiology, pathophysiology, and treatments,” Cardiology Clinics, vol. 34, no. 3, pp. 413–433, 2016. View at Publisher · View at Google Scholar
  5. M. M. Hoeper, H. J. Bogaard, R. Condliffe et al., “Definitions and diagnosis of pulmonary hypertension,” Journal of the American College of Cardiology, vol. 62, no. 25, pp. D42–D50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Hansdottir, D. J. Groskreutz, and B. K. Gehlbach, “WHO's in second?: a practical review of world health organization group 2 pulmonary hypertension,” Chest, vol. 144, no. 2, pp. 638–650, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. H. D. Poor, R. Girgis, and S. M. Studer, “World Health Organization Group III pulmonary hypertension,” Progress in Cardiovascular Diseases, vol. 55, no. 2, pp. 119–127, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. C. E. Ventetuolo and J. R. Klinger, “WHO Group 1 pulmonary arterial hypertension: current and investigative therapies,” Progress in Cardiovascular Diseases, vol. 55, no. 2, pp. 89–103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Simonneau, I. M. Robbins, M. Beghetti et al., “Updated clinical classification of pulmonary hypertension,” Journal of the American College of Cardiology, vol. 54, no. 1, pp. S43–S54, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Agrawal, I. Verma, V. Shah, A. Agarwal, and R. R. Sikachi, “Cardiac manifestations of idiopathic pulmonary fibrosis,” Intractable & Rare Diseases Research, vol. 5, no. 2, pp. 70–75, 2016. View at Publisher · View at Google Scholar
  11. G. Raghu, D. Weycker, J. Edelsberg, W. Z. Bradford, and G. Oster, “Incidence and prevalence of idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 7, pp. 810–816, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. N. M. Patel, D. J. Lederer, A. C. Borczuk, and S. M. Kawut, “Pulmonary hypertension in idiopathic pulmonary fibrosis,” Chest, vol. 132, no. 3, pp. 998–1006, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Raghu, J. Behr, K. K. Brown et al., “Treatment of idiopathic pulmonary fibrosis with ambrisentan A parallel, Randomized Trial,” Annals of Internal Medicine, vol. 158, no. 9, pp. 641–649, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. C. J. Lettieri, S. D. Nathan, S. D. Barnett, S. Ahmad, and A. F. Shorr, “Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis,” Chest, vol. 129, no. 3, pp. 746–752, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. F. Shorr, J. L. Wainright, C. S. Cors, C. J. Lettieri, and S. D. Nathan, “Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant,” European Respiratory Journal, vol. 30, no. 4, pp. 715–721, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. R. A. Dweik, S. Rounds, S. C. Erzurum et al., “An official American Thoracic Society statement: pulmonary hypertension phenotypes,” American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 3, pp. 345–355, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. R. D. Machado, L. Southgate, C. A. Eichstaedt et al., “Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects,” Human Mutation, vol. 36, no. 12, pp. 1113–1127, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. K. B. Martin, J. R. Klinger, and S. I. S. Rounds, “Pulmonary arterial hypertension: new insights and new hope,” Respirology, vol. 11, no. 1, pp. 6–17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. O'Brien and S. Rounds, “Pulmonary hypertension update,” Comprehensive Therapy, vol. 26, no. 3, pp. 190–196, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. B. A. Helling and I. V. Yang, “Epigenetics in lung fibrosis: from pathobiology to treatment perspective,” Current Opinion in Pulmonary Medicine, vol. 21, no. 5, pp. 454–462, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Tzouvelekis and N. Kaminski, “Epigenetics in idiopathic pulmonary fibrosis,” Biochemistry and Cell Biology, vol. 93, no. 2, pp. 159–170, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. I. V. Yang, “Epigenomics of idiopathic pulmonary fibrosis,” Epigenomics, vol. 4, no. 2, pp. 195–203, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. I. V. Yang and D. A. Schwartz, “Epigenetics of idiopathic pulmonary fibrosis,” Translational Research, vol. 165, no. 1, pp. 48–60, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. J. H. Huston and J. J. Ryan, “The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials (2015 Grover Conference Series),” Pulmonary Circulation, vol. 6, no. 3, pp. 274–284, 2016. View at Publisher · View at Google Scholar
  25. J. Kim, A. Lee, J. Choi et al., “Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension,” Experimental & Molecular Medicine, vol. 47, no. 7, article no. e175, 2015. View at Publisher · View at Google Scholar
  26. X.-F. Xu, F. Cheng, and L.-Z. Du, “Epigenetic regulation of pulmonary arterial hypertension,” Hypertension Research, vol. 34, no. 9, pp. 981–986, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Hu, M. Gharaee-Kermani, Z. Wu, and S. H. Phan, “Epigenetic regulation of myofibroblast differentiation by DNA methylation,” The American Journal of Pathology, vol. 177, no. 1, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. R. A. Philibert, R. A. Sears, L. S. Powers et al., “Coordinated DNA methylation and gene expression changes in smoker alveolar macrophages: specific effects on VEGF receptor 1 expression,” Journal of Leukocyte Biology, vol. 92, no. 3, pp. 621–631, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. E. S. Wan, W. Qiu, A. Baccarelli et al., “Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome,” Human Molecular Genetics, vol. 21, no. 13, pp. 3073–3082, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Giaid, M. Yanagisawa, D. Langleben et al., “Expression of endothelin-1 in the lungs of patients with pulmonary hypertension,” New England Journal of Medicine, vol. 328, no. 24, pp. 1732–1739, 1993. View at Publisher · View at Google Scholar · View at Scopus
  31. C. E. Ventetuolo, S. M. Kawut, and D. J. Lederer, “Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis,” Respiration, vol. 84, no. 4, pp. 299–305, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Giaid, R. P. Michel, D. Stewart, M. Sheppard, Q. Hamid, and B. Corrin, “Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis,” The Lancet, vol. 341, no. 8860, pp. 1550–1554, 1993. View at Publisher · View at Google Scholar · View at Scopus
  33. D. M. Pollock, T. L. Keith, and R. F. Highsmith, “Endothelin receptors and calcium signaling,” FASEB Journal, vol. 9, no. 12, pp. 1196–1204, 1995. View at Google Scholar · View at Scopus
  34. A. Matsuura, W. Yamochi, K.-I. Hirata, S. Kawashima, and M. Yokoyama, “Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression,” Hypertension, vol. 32, no. 1, pp. 89–95, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. G. F. Alberts, K. A. Peifley, A. Johns, J. F. Kleha, and J. A. Winkles, “Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop,” Journal of Biological Chemistry, vol. 269, no. 13, pp. 10112–10118, 1994. View at Google Scholar · View at Scopus
  36. M. Marini, S. Carpi, A. Bellini, F. Patalano, and S. Mattoli, “Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells,” Biochemical and Biophysical Research Communications, vol. 220, no. 3, pp. 896–899, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Iglarz, A. Bossu, D. Wanner et al., “Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension,” Life sciences, vol. 118, no. 2, pp. 333–339, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Schroll, M. Arzt, D. Sebah, M. Nüchterlein, F. Blumberg, and M. Pfeifer, “Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan,” Respiratory Physiology and Neurobiology, vol. 170, no. 1, pp. 32–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. Z. Wang, N. Jin, S. Ganguli, D. R. Swartz, L. Li, and R. A. Rhoades, “Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction,” American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 5, pp. 628–635, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Bei, T. Hua-Huy, S. Duong-Quy et al., “Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation,” Pulmonary Pharmacology and Therapeutics, vol. 26, no. 6, pp. 635–643, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Homma, T. Nagaoka, V. Karoor et al., “Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 295, no. 1, pp. L71–L78, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Gien, N. Tseng, G. Seedorf, K. Kuhn, and S. H. Abman, “Endothelin-1—Rho kinase interactions impair lung structure and cause pulmonary hypertension after bleomycin exposure in neonatal rat pups,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 311, no. 6, pp. L1090–L1100, 2016. View at Publisher · View at Google Scholar
  43. A. H. Lee, R. Dhaliwal, C. Kantores et al., “Rho-Kinase inhibitor prevents bleomycin-induced injury in neonatal rats independent of effects on lung inflammation,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 1, pp. 61–73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Loirand, P. Guérin, and P. Pacaud, “Rho kinases in cardiovascular physiology and pathophysiology,” Circulation Research, vol. 98, no. 3, pp. 322–334, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. P. J. McNamara, P. Murthy, C. Kantores et al., “Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 294, no. 2, pp. L205–L213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Fujita, Y. Fukumoto, K. Saji et al., “Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension,” Heart and Vessels, vol. 25, no. 2, pp. 144–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Ishikura, N. Yamada, M. Ito et al., “Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension,” Circulation Journal, vol. 70, no. 2, pp. 174–178, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. H. A. Ghofrani, R. Wiedemann, F. Rose et al., “Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial,” The Lancet, vol. 360, no. 9337, pp. 895–900, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. A. R. Hemnes, A. Zaiman, and H. C. Champion, “PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 294, no. 1, pp. L24–L33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Khan, A. Agrotis, and A. Bobik, “Understanding the role of transforming growth factor-β1 in intimal thickening after vascular injury,” Cardiovascular Research, vol. 74, no. 2, pp. 223–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Nakerakanti and M. Trojanowska, “The role of TGF-β receptors in fibrosis,” Open Rheumatology Journal, vol. 6, no. 1, pp. 156–162, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Moustakas and C.-H. Heldin, “Non-Smad TGF-β signals,” Journal of Cell Science, vol. 118, no. 16, pp. 3573–3584, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Agrotis, N. Kalinina, and A. Bobik, “Transforming growth factor-β, cell signaling and cardiovascular disorders,” Current Vascular Pharmacology, vol. 3, no. 1, pp. 55–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Wilborn, L. J. Crofford, M. O. Burdick, S. L. Kunkel, R. M. Strieter, and M. Peters- Golden, “Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2,” Journal of Clinical Investigation, vol. 95, no. 4, pp. 1861–1868, 1995. View at Publisher · View at Google Scholar · View at Scopus
  55. R. J. McAnulty, N. A. Hernández-Rodríguez, S. E. Mutsaers, R. K. Coker, and G. J. Laurent, “Indomethacin suppresses the anti-proliferative effects of transforming growth factor-β isoforms on fibroblast cell cultures,” Biochemical Journal, vol. 321, no. 3, pp. 639–643, 1997. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Gilboa, A. Nohe, T. Geissendörfer, W. Sebald, Y. I. Henis, and P. Knaus, “Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors,” Molecular Biology of the Cell, vol. 11, no. 3, pp. 1023–1035, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. N.-Y. Chen, S. D. Collum, F. Luo et al., “Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 311, no. 2, pp. L238–L254, 2016. View at Publisher · View at Google Scholar · View at Scopus
  58. A. J. Bryant, L. J. Robinson, C. S. Moore et al., “Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis,” Pulmonary Circulation, vol. 5, pp. 681–690, 2015. View at Google Scholar
  59. B. C. Cooley, J. Nevado, J. Mellad et al., “TGF-β signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling,” Science Translational Medicine, vol. 6, no. 227, Article ID 227ra34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Hashimoto, S. H. Phan, K. Imaizumi et al., “Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 43, no. 2, pp. 161–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. T. J. Corte, G. J. Keir, K. Dimopoulos et al., “Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia,” American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 2, pp. 208–217, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. A. J. Bryant, R. P. Carrick, M. E. McConaha et al., “Endothelial hif signaling regulates pulmonary fibrosis-associated pulmonary hypertension,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 310, no. 3, pp. L249–L262, 2016. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Iwai, K. Yamanaka, T. Kamura et al., “Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 22, pp. 12436–12441, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. M. M. Hickey, T. Richardson, T. Wang et al., “The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice,” Journal of Clinical Investigation, vol. 120, no. 3, pp. 827–839, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Cui, J. Robertson, S. Maharaj et al., “Oxidative stress contributes to the induction and persistence of TGF-β1 induced pulmonary fibrosis,” International Journal of Biochemistry and Cell Biology, vol. 43, no. 8, pp. 1122–1133, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Delaney, R. H. Wright, J.-R. Tang et al., “Lack of EC-SOD worsens alveolar and vascular development in a neonatal mouse model of bleomycin-induced bronchopulmonary dysplasia and pulmonary hypertension,” Pediatric Research, vol. 78, no. 6, pp. 634–640, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. E. Nozik-Grayck, C. Woods, J. M. Taylor et al., “Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 307, no. 11, pp. L868–L876, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. A. C. P. Sewing, C. Kantores, J. Ivanovska et al., “Therapeutic hypercapnia prevents bleomycin-induced pulmonary hypertension in neonatal rats by limiting macrophage-derived tumor necrosis factor-α,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 303, no. 1, pp. L75–L87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. R. B. Patel, S. R. Kotha, L. A. Sauers et al., “Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: comparison between classical thiol-protectant, N-acetyl-l-cysteine, and novel thiol antioxidant, N,N′-bis-2-mercaptoethyl isophthalamide,” Toxicology Mechanisms and Methods, vol. 22, no. 5, pp. 383–396, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Almudéver, J. Milara, A. De Diego et al., “Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis,” Thorax, vol. 68, no. 10, pp. 938–948, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Grasemann, R. Dhaliwal, J. Ivanovska et al., “Arginase inhibition prevents bleomycin-induced pulmonary hypertension, vascular remodeling, and collagen deposition in neonatal rat lungs,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 308, no. 6, pp. L503–L510, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Eckle, E. M. Kewley, K. S. Brodsky et al., “Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury,” Journal of Immunology, vol. 192, no. 3, pp. 1249–1256, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Zhou, D. J. Schneider, and M. R. Blackburn, “Adenosine signaling and the regulation of chronic lung disease,” Pharmacology and Therapeutics, vol. 123, no. 1, pp. 105–116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Zhou, D. J. Schneider, E. Morschl et al., “Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury,” Journal of Immunology, vol. 186, no. 2, pp. 1097–1106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Zhou, J. N. Murthy, D. Zeng, L. Belardinelli, and M. R. Blackburn, “Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis,” PLoS ONE, vol. 5, no. 2, Article ID e9224, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Karmouty-Quintana, H. Zhong, L. Acero et al., “The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease,” FASEB Journal, vol. 26, no. 6, pp. 2546–2557, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Karmouty-Quintana, T. Weng, L. J. Garcia-Morales et al., “Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with Chronic obstructive pulmonary disease,” American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 6, pp. 1038–1047, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Karmouty-Quintana, K. Philip, L. F. Acero et al., “Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension,” FASEB Journal, vol. 29, no. 1, pp. 50–60, 2015. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Kalay, D. Elcik, H. Canatan et al., “Elevated plasma hyaluronan levels in pulmonary hypertension,” Tohoku Journal of Experimental Medicine, vol. 230, no. 1, pp. 7–11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Aytekin and R. A. Dweik, “Low-molecular-mass of hyaluronan was detected in PASMCs from the patients with idiopathic pulmonary arterial hypertension,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 300, no. 1, article L148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Aytekin, S. A. A. Comhair, C. De La Motte et al., “High levels of hyaluronan in idiopathic pulmonary arterial hypertension,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 295, no. 5, pp. L789–L799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Brock, M. Trenkmann, R. E. Gay et al., “Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway,” Circulation Research, vol. 104, no. 10, pp. 1184–1191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. M. K. Steiner, O. L. Syrkina, N. Kolliputi, E. J. Mark, C. A. Hales, and A. B. Waxman, “Interleukin-6 overexpression induces pulmonary hypertension,” Circulation Research, vol. 104, no. 2, pp. 236–244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. L. J. Garcia-Morales, N.-Y. Chen, T. Weng et al., “Altered hypoxic-adenosine axis and metabolism in group III pulmonary hypertension,” American Journal of Respiratory Cell and Molecular Biology, vol. 54, no. 4, pp. 574–583, 2016. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Le Thanh-Thuy, H. Karmouty-Quintana, E. Melicoff et al., “Blockade of IL-6 trans signaling attenuates pulmonary fibrosis,” Journal of Immunology, vol. 193, no. 7, pp. 3755–3768, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. L. Savale, L. Tu, D. Rideau et al., “Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice,” Respiratory Research, vol. 10, article no. 6, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. A. L. Degryse and W. E. Lawson, “Progress toward improving animal models for idiopathic pulmonary fibrosis,” The American Journal of the Medical Sciences, vol. 341, no. 6, pp. 444–449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. B. B. Moore, W. E. Lawson, T. D. Oury, T. H. Sisson, K. Raghavendran, and C. M. Hogaboam, “Animal models of fibrotic lung disease,” American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 2, pp. 167–179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. C. P. Baran, J. M. Opalek, S. McMaken et al., “Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 1, pp. 78–89, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. Z. Van Rheen, C. Fattman, S. Domarski et al., “Lung extracellular superoxide dismutase overexpression lessens bleomycin-induced pulmonary hypertension and vascular remodeling,” American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 4, pp. 500–508, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. J. L. Chunn, J. G. Molina, T. Mi, Y. Xia, R. E. Kellems, and M. R. Blackburn, “Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice,” Journal of Immunology, vol. 175, no. 3, pp. 1937–1946, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Eferl, P. Hasselblatt, M. Rath et al., “Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10525–10530, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. E. C. Derrett-Smith, A. Dooley, A. J. Gilbane et al., “Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension,” Arthritis and Rheumatism, vol. 65, no. 11, pp. 2928–2939, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. N. F. Voelkel, R. A. Quaife, L. A. Leinwand et al., “Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure,” Circulation, vol. 114, no. 17, pp. 1883–1891, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Moriarty, “The law of Laplace. Its limitations as a relation for diastolic pressure, volume, or wall stress of the left ventricle,” Circulation Research, vol. 46, no. 3, pp. 321–331, 1980. View at Publisher · View at Google Scholar · View at Scopus
  96. E. Weitzenblum, “Chronic cor pulmonale,” Heart, vol. 89, no. 2, pp. 225–230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. T. Kuehne, S. Yilmaz, P. Steendijk et al., “Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension,” Circulation, vol. 110, no. 14, pp. 2010–2016, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. C. A. Dias, R. S. Assad, L. F. Caneo et al., “Reversible pulmonary trunk banding. II. An experimental model for rapid pulmonary ventricular hypertrophy,” Journal of Thoracic and Cardiovascular Surgery, vol. 124, no. 5, pp. 999–1006, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. D. S. Schulman and R. A. Matthay, “The right ventricle in pulmonary disease,” Cardiology Clinics, vol. 10, no. 1, pp. 111–135, 1992. View at Google Scholar · View at Scopus
  100. A. Zangiabadi, C. G. De Pasquale, and D. Sajkov, “Pulmonary hypertension and right heart dysfunction in chronic lung disease,” BioMed Research International, vol. 2014, Article ID 739674, 13 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. R. H. Behnke, S. G. Blount, J. D. Bristow et al., “Primary prevention of pulmonary heart disease,” Journal of the American Osteopathic Association, vol. 69, no. 11, pp. 1139–1146, 1970. View at Google Scholar · View at Scopus
  102. M. S. Niederman and R. A. Matthay, “Cardiovascular function in secondary pulmonary hypertension,” Heart and Lung: Journal of Acute and Critical Care, vol. 15, no. 4, pp. 341–351, 1986. View at Google Scholar · View at Scopus
  103. M. M. Budev, A. C. Arroliga, H. P. Wiedemann, and R. A. Matthay, “Cor pulmonale: an overview,” Seminars in Respiratory and Critical Care Medicine, vol. 24, no. 3, pp. 233–244, 2003. View at Publisher · View at Google Scholar · View at Scopus
  104. E. Weitzenblum, M. Ehrhart, J. Rasaholinjanahary, and C. Hirth, “Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases,” Respiration, vol. 44, no. 2, pp. 118–127, 1983. View at Publisher · View at Google Scholar · View at Scopus
  105. T. M. Kolb and P. M. Hassoun, “Right ventricular dysfunction in chronic lung disease,” Cardiology Clinics, vol. 30, no. 2, pp. 243–256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. K. Sietsema, “Cardiovascular limitations in chronic pulmonary disease,” Medicine and Science in Sports and Exercise, vol. 33, no. 7, pp. S656–S661, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. C. C. W. Hsia, “Cardiopulmonary limitations to exercise in restrictive lung disease,” Medicine and Science in Sports and Exercise, vol. 31, no. 1, pp. S28–S32, 1999. View at Publisher · View at Google Scholar · View at Scopus
  108. S. D. Nathan, P. W. Noble, and R. M. Tuder, “Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 9, pp. 875–880, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. M. L. Handoko, F. S. De Man, C. P. Allaart, W. J. Paulus, N. Westerhof, and A. Vonk-Noordegraaf, “Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart,” European Respiratory Review, vol. 19, no. 115, pp. 72–82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. M. McGoon, D. Gutterman, V. Steen et al., “Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines,” Chest, vol. 126, no. 1, pp. 14S–34S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. B. N. Rivera-Lebron, P. R. Forfia, M. Kreider, J. C. Lee, J. H. Holmes, and S. M. Kawut, “Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis,” Chest, vol. 144, no. 2, pp. 564–570, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. S. M. Arcasoy, J. D. Christie, V. A. Ferrari et al., “Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 5, pp. 735–740, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. A. D'Andrea, A. Stanziola, M. D'Alto et al., “Right ventricular strain: an independent predictor of survival in idiopathic pulmonary fibrosis,” International Journal of Cardiology, vol. 222, pp. 908–910, 2016. View at Publisher · View at Google Scholar · View at Scopus
  114. A. D'Andrea, A. Stanziola, E. Di Palma et al., “Right ventricular structure and function in idiopathic pulmonary fibrosis with or without pulmonary hypertension,” Echocardiography, vol. 33, no. 1, pp. 57–65, 2016. View at Publisher · View at Google Scholar · View at Scopus
  115. W. Macnee, “Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease: part two,” American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 4, pp. 1158–1168, 1994. View at Publisher · View at Google Scholar · View at Scopus
  116. M. M. Hoeper, S. Andreas, A. Bastian et al., “Pulmonary hypertension due to chronic lung disease: updated recommendations of the cologne consensus conference 2011,” International Journal of Cardiology, vol. 154, no. 1, pp. S45–S53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. R. A. Incalzi, L. Fuso, M. De Rosa et al., “Electrocardiographic signs of chronic cor pulmonale: a negative prognostic finding in chronic obstructive pulmonary disease,” Circulation, vol. 99, no. 12, pp. 1600–1605, 1999. View at Publisher · View at Google Scholar · View at Scopus
  118. B. Burrows, L. J. Kettel, A. H. Niden, M. Rabinowitz, and C. F. Diener, “Patterns of cardiovascular dysfunction in chronic obstructive lung disease,” New England Journal of Medicine, vol. 286, no. 17, pp. 912–918, 1972. View at Publisher · View at Google Scholar · View at Scopus
  119. G. Giannakoulas, T. D. Karamitsos, G. Pitsiou, and H. I. Karvounis, “Right ventricular dysfunction and functional limitation in idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 31, no. 1, pp. 219–220, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. H. H. Leuchte, C. Neurohr, R. Baumgartner et al., “Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 4, pp. 360–365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  121. J. W. Song, J.-K. Song, and D. S. Kim, “Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis,” Respiratory Medicine, vol. 103, no. 2, pp. 180–186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. H. H. Leuchte, R. A. Baumgartner, M. El Nounou et al., “Brain natriuretic peptide is a prognostic parameter in chronic lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 7, pp. 744–750, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. R. A. Pauwels, A. S. Buist, P. M. A. Calverley, C. R. Jenkins, and S. S. Hurd, “Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 5, pp. 1256–1276, 2001. View at Publisher · View at Google Scholar · View at Scopus
  124. A. Sachdev, H. R. Villarraga, R. P. Frantz et al., “Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension,” Chest, vol. 139, no. 6, pp. 1299–1309, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. L. Richeldi, U. Costabel, M. Selman et al., “Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis,” New England Journal of Medicine, vol. 365, no. 12, pp. 1079–1087, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. Idiopathic Pulmonary Fibrosis Clinical Research Network, G. Raghu, K. J. Anstrom, T. E. King Jr., J. A. Lasky, and F. J. Martinez, “Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis,” The New England Journal of Medicine, vol. 366, no. 21, pp. 1968–1977, 2012. View at Publisher · View at Google Scholar
  127. T. E. King Jr., W. Z. Bradford, S. Castro-Bernardini et al., “A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis,” New England Journal of Medicine, vol. 370, no. 22, pp. 2083–2092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. P. W. Noble, C. Albera, W. Z. Bradford et al., “Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials,” The Lancet, vol. 377, no. 9779, pp. 1760–1769, 2011. View at Publisher · View at Google Scholar · View at Scopus
  129. U. Costabel, C. Albera, W. Z. Bradford et al., “Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 31, no. 3, pp. 198–205, 2014. View at Google Scholar · View at Scopus
  130. E. M. T. Lau, Y. Tamura, M. D. McGoon, and O. Sitbon, “The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress,” The European Respiratory Journal, vol. 46, no. 4, pp. 879–882, 2015. View at Publisher · View at Google Scholar · View at Scopus
  131. H. Olschewski, H. A. Ghofrani, D. Walmrath et al., “Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 2, pp. 600–607, 1999. View at Publisher · View at Google Scholar · View at Scopus
  132. D. A. Zisman, M. Schwarz, K. J. Anstrom, H. R. Collard, K. R. Flaherty, and G. W. Hunninghake, “A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 363, pp. 620–628, 2010. View at Google Scholar
  133. T. E. King Jr., J. Behr, K. K. Brown et al., “BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 1, pp. 75–81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. H.-A. Ghofrani, N. Galiè, F. Grimminger et al., “Riociguat for the treatment of pulmonary arterial hypertension,” New England Journal of Medicine, vol. 369, no. 4, pp. 330–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  135. H.-A. Ghofrani, A. M. D'Armini, F. Grimminger et al., “Riociguat for the treatment of chronic thromboembolic pulmonary hypertension,” New England Journal of Medicine, vol. 369, no. 4, pp. 319–329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. M. M. Hoeper, M. Halank, H. Wilkens et al., “Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial,” European Respiratory Journal, vol. 41, no. 4, pp. 853–860, 2013. View at Publisher · View at Google Scholar · View at Scopus
  137. L. Richeldi, R. M. Du Bois, G. Raghu et al., “Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis,” New England Journal of Medicine, vol. 370, no. 22, pp. 2071–2082, 2014. View at Publisher · View at Google Scholar · View at Scopus
  138. T. Ogura, H. Taniguchi, A. Azuma et al., “Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 45, no. 5, pp. 1382–1392, 2015. View at Publisher · View at Google Scholar · View at Scopus
  139. P. Minnis and J. Egan, “The use of pirfenidone in combination with sildenafil for advanced idiopathic pulmonary fibrosis,” in A38 Diamonds Are Forever But New Treatments for Interstitial Lung Disease Can't Wait, vol. 189, p. A1432, American Journal of Respiratory and Critical Care Medicine, 2014. View at Google Scholar
  140. Y.-W. Lan, K.-B. Choo, C.-M. Chen et al., “Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis,” Stem Cell Research and Therapy, vol. 6, no. 1, article 97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  141. L. A. Ortiz, F. Gambelli, C. McBride et al., “Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8407–8411, 2003. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Reddy, L. Fonseca, S. Gowda, B. Chougule, A. Hari, and S. Totey, “Human adipose-derived mesenchymal stem cells attenuate early stage of bleomycin induced pulmonary fibrosis: comparison with pirfenidone,” International Journal of Stem Cells, vol. 9, no. 2, pp. 192–206, 2016. View at Publisher · View at Google Scholar
  143. M. Rojas, J. Xu, C. R. Woods et al., “Bone marrow-derived mesenchymal stem cells in repair of the injured lung,” American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 2, pp. 145–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  144. L. Luo, T. Lin, S. Zheng et al., “Adipose-derived stem cells attenuate pulmonary arterial hypertension and ameliorate pulmonary arterial remodeling in monocrotaline-induced pulmonary hypertensive rats,” Clinical and Experimental Hypertension, vol. 37, no. 3, pp. 241–248, 2015. View at Publisher · View at Google Scholar · View at Scopus
  145. C. M. Suen, S. H. J. Mei, L. Kugathasan, and D. J. Stewart, “Targeted delivery of genes to endothelial cells and cell- and gene-based therapy in pulmonary vascular diseases,” Comprehensive Physiology, vol. 3, no. 4, pp. 1749–1779, 2013. View at Publisher · View at Google Scholar · View at Scopus
  146. Y. D. Zhao, D. W. Courtman, Y. Deng, L. Kugathasan, Q. Zhang, and D. J. Stewart, “Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease,” Circulation Research, vol. 96, no. 4, pp. 442–450, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. A. Tzouvelekis, V. Paspaliaris, G. Koliakos et al., “A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis,” Journal of Translational Medicine, vol. 11, no. 1, article no. 171, 2013. View at Publisher · View at Google Scholar · View at Scopus
  148. X.-X. Wang, F.-R. Zhang, Y.-P. Shang et al., “Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial,” Journal of the American College of Cardiology, vol. 49, no. 14, pp. 1566–1571, 2007. View at Publisher · View at Google Scholar · View at Scopus